MedPath

Comparing a vaginal tablet (Misoprostol) and device (Dilapan) kept inside the cervix for dilatation of cervix before operative hysterosocpic procedures

Not Applicable
Conditions
Health Condition 1: N99- Intraoperative and postproceduralcomplications and disorders of genitourinary system, not elsewhere classified
Registration Number
CTRI/2020/04/024844
Lead Sponsor
Jawaharlal Institute of Postgraduate Medical Education and Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Women of age 18 years or more, scheduled for operative hysteroscopic procedures with 26F resectoscope

Exclusion Criteria

Cervical incompetence

Contraindication to Misoprostol use like history of severe asthma, glaucoma, preexisting cardiac disease, hypertension, or renal failure

Significant uterovaginal prolapse precluding the administration of vaginal tablets.

Pelvic inflammatory disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The need for mechanical dilatation, following vaginal Misoprostol or synthetic osmotic dilator (Dilapan) for cervical preparation prior to operative hysteroscopy. <br/ ><br> <br/ ><br>Timepoint: 12 hours after insertion <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
The side effects and complications of Misoprostol and synthetic osmotic dilator (Dilapan) <br/ ><br> <br/ ><br>Timepoint: 3 weeks
© Copyright 2025. All Rights Reserved by MedPath